In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
386 News Items found
Amy Speck
Feature
Robotic Neurosurgery at MSK Speeds Recovery From Some Spinal Tumors

MSK surgeons have regularly used robotic surgery since 2007 to remove certain tumors in the chest and abdominal cavity. Now they are using robotic surgery to remove noncancerous tumors of the spine.
Gloved hand and magnifying glass on banded DNA sequences
Announcement
FDA Authorizes MSK-IMPACT Test for Analyzing Patient Tumors

The test, developed at MSK, looks for alterations in 468 genes that are seen in both common and rare cancers.
Dermatologist examining skin on the face of older man.
In the Clinic
Immunotherapy Drug Shows Promise for Metastatic Merkel Cell Carcinoma

An immunotherapy drug might be an effective initial treatment for people with metastatic Merkel cell carcinoma.
Memorial Sloan Kettering surgeon Daniela Molena
In the Clinic
When Is Heartburn a Sign of Esophageal Cancer?

Many people don’t know that gastroesophageal reflux disease (GERD) is a potentially serious condition that — if left untreated — can ultimately lead to esophageal cancer.
Pictured: Eric Holland, Franziska Michor, and Desert Horse-Grant
New Center Uses Mathematical Models to Understand Cancer

In October 2009, a team of eight researchers, six of whom are at Memorial Sloan Kettering, received an $11 million, five-year grant from the NCI to form one of 12 Physical Sciences-Oncology Centers (PS-OCs) in the United States.
Scientists at the Sloan Kettering Institute are learning why some immune cells are stubbornly hard to revive with immunotherapy.
In the Lab
Why Immune Cells Sometimes Fail to Fight Cancer (and What to Do about It)

By looking at how DNA is packaged in cells, scientists are teasing apart a long-standing conundrum about the immune response to cancer.
Francis M. Sirotnak
FDA Approves Lymphoma Drug Developed at Memorial Sloan Kettering

Patients with a rare but aggressive form of cancer now have access to a drug that has proven effective after the disease becomes resistant to standard treatments.
Illustration of breast cancer cell
In the Clinic
Targeted Drug Shows Promise Against HER2-Positive Breast Cancer That Stops Responding to Other Drugs

MSK medical oncologist Shanu Modi is the lead author of a new paper detailing the results from a phase II trial of a breast cancer drug called trastuzumab deruxtecan or DS-8201a. Results from this study were also presented at the San Antonio Breast Cancer Symposium.
Dennis Flaherty
Feature
How MSK Is Helping Dennis Survive Stage 4 Kidney Cancer

When Dennis Flaherty was diagnosed with stage 4 kidney cancer, he knew he wanted to be treated at MSK. His story illustrates why U.S. News & World Report ranked MSK the top hospital in the country for urology care in 2023.
Pictured: David Solit
Profile
At Work: Physician-Scientist David Solit

David Solit, Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, discusses how working with cancer patients drives him to develop more-effective, personalized cancer treatments.